China's Bio-Thera gets approval for Humira biosimilar
China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world's second-largest drug market. (Source: Reuters: Health)
Source: Reuters: Health - November 7, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx (secukinumab) can beat the world ' s best-selling drug Humira (adalimumab) in treating a type of arthritis.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 5, 2019 Category: Orthopaedics Tags: Rheumatology News Source Type: news
Novartis Cosentyx ® shows encouraging results versus Humira® from first-of-its-kind head-to-head trial in psoriatic arthritis
Novartis, a leader in rheumatology and immuno-dermatology, announced results from the EXCEED head-to-head trial comparing Cosentyx® (secukinumab) to Humira®* (adalimumab) in patients with active psoriatic arthritis (PsA)[1]. While Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, it showed numerically higher results versus Humira®*[1]. (Source: World Pharma News)
Source: World Pharma News - November 4, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Novartis arthritis drug " narrowly misses " against Humira
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug, Cosentyx, can beat the world ' s best-selling drug Humira in treating arthritis. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 1, 2019 Category: Pharmaceuticals Source Type: news
Risk for Birth Defects Not Increased With Adalimumab
FRIDAY, Nov. 1, 2019 -- Adalimumab exposure in pregnancy does not increase the risk for birth defects, according to a study published online Oct. 18 in PLOS ONE.
Christina D. Chambers, from the University of California San Diego in La Jolla, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 1, 2019 Category: Pharmaceuticals Source Type: news
Novartis arthritis drug falls short in challenge to global bestseller
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world's best-selling drug Humira in treating a type of arthritis. (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Therapeutic IBD Drug Concentrations May Vary With Different Assays Therapeutic IBD Drug Concentrations May Vary With Different Assays
In patients with inflammatory bowel disease (IBD), concentrations of infliximab and adalimumab varied depending on whether they were assessed with the Enzyme-Linked Immunosorbent Assay (ELISA) or the Homogeneous Mobility Shift Assay (HMSA), researchers found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Study Suggests Adalimumab Exposure in Pregnancy Does Not Increase...
602 Pregnancies Examined by the Non-Profit Organization of Teratology Information Specialists(PRWeb October 18, 2019)Read the full story at https://www.prweb.com/releases/study_suggests_adalimumab_exposure_in_pregnancy_does_not_increase_birth_defects_risk/prweb16660500.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 18, 2019 Category: Pharmaceuticals Source Type: news
Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report
Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 10, 2019 Category: Infectious Diseases Tags: Public Health & Prevention News Source Type: news
Humira, Rituxan top list of U.S. drugs with biggest price increases: report
AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. (Source: Reuters: Health)
Source: Reuters: Health - October 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Cyltezo (Adalimumab-ADBM Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 26, 2019 Category: Drugs & Pharmacology Source Type: news
Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions
WEDNESDAY, Sept. 25, 2019 -- In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission, and ustekinumab is superior to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 25, 2019 Category: Pharmaceuticals Source Type: news
Adalimumab procurement framework extended
NHS England has extended the procurement framework for adalimumab by four months to 31 March 2020. (Source: NHS Networks)
Source: NHS Networks - September 8, 2019 Category: UK Health Source Type: news
NHS saves £300MILLION in a year by telling doctors to stop giving out expensive branded medications
Hospitals spent £290million on adalimumab - a drug primarily used to treat arthritis but also given to patients with Crohn's disease - in 2018/19. (Source: the Mail online | Health)
Source: the Mail online | Health - August 31, 2019 Category: Consumer Health News Source Type: news
These are the top 25 costliest prescription drugs for Oregon insurers
Humira is the best-selling medicine in the world and a gold mine for drug maker AbbVie, bringing in $4.87 billion in revenue globally in the second quarter.
The drug, which treats rheumatoid arthritis and Crohn's disease, costs upwards of $60,000 a year.
So it may come as no surprise that Humira is on the list of the 25 most costly drugs for Oregon health insurers in 2018.
The combined list is based on the rankings submitted by nine insurance comp anies and takes into account total annual spending,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 20, 2019 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news
